Search results
4 dni temu · Multiple myeloma (MM) is the second most common malignant hematologic disease. Bone involvement is one of the most common symptoms of MM (the acronym CRAB describes the most common clinical signs: hypercalcemia, renal impairment, anemia, and bone disease). Therefore, substantial morbidity, physical impairment, compression fractures, pain, and ...
2 dni temu · Advances in treatment have improved the survival of multiple myeloma (MM) patients, but the disease remains incurable. Here, in this nationwide retrospective real-world evidence (RWE) study, we report the patient characteristics, incidence, overall survival outcomes, comorbidities, and healthcare resource utilization (HCRU) of all adult MM patients diagnosed between 2000 and 2021 in Finland. A ...
19 godz. temu · Introduction: According to the National Cancer Institute of the NIH, acute myeloid leukemia (AML) is a rapidly growing cancer with a large quantity of myeloblasts. AML is most often observed in adults over the age of 35, accounting for 1% of all cancer types. In 2023, the number of new cases being reported was estimated to reach around 20,380 in total and the rate of mortality in the same year ...
5 dni temu · Multiple myeloma is one of the most common forms of cancer of the immune cells in the bone marrow. It is considered incurable. Even when patients respond to treatment at first, the cancer comes...
3 dni temu · The FDA approved cilta-cel in relapsed/refractory multiple myeloma following at least 1 prior line of therapy in April 2024. 3 Supporting data for the approval came from the CARDITUDE-4 trial. Findings showed that cilta-cel conferred a 59% reduction in the risk of disease progression compared with PVd or DPd.
5 dni temu · Multiple myeloma is one of the most common forms of cancer of the immune cells in the bone marrow. It is considered incurable. Even when patients respond to treatment at first, the cancer comes...
5 dni temu · Multiple myeloma is one of the most common forms of cancer of the immune cells in the bone marrow. It is considered incurable. Even when patients respond to treatment at first, the cancer comes back. To be able to intervene faster and on a more targeted basis, researchers at Charité – Universitätsmedizin Berlin, the Berlin Institute of Health at Charité (BIH), and the Max Delbrück Center ...
